26,248 Shares of Twist Bioscience Corporation $TWST Bought by Calamos Advisors LLC

Key Points

• Calamos Advisors initiated a position in Twist Bioscience, buying 26,248 shares worth approximately $5.07 million in the third quarter.
• Several other institutional investors also reported new positions, including BlackRock, whose stake was valued at about $600.2 million.
• Insiders sold 495,279 shares worth roughly $80.5 million over the past 90 days; the reported individual sales were to cover taxes on vested equity awards. Analysts’ consensus rating is Hold, with a $153 average price target.

Calamos Advisors LLC purchased a new position in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 26,248 shares of the company's stock, valued at approximately $5,072,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Twist Bioscience during the 2nd quarter valued at approximately $600,191,000. William Blair Investment Management LLC acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $223,722,000. Bank of America Corp DE acquired a new stake in Twist Bioscience during the 2nd quarter worth approximately $94,922,000. Allspring Global Investments Holdings LLC acquired a new stake in Twist Bioscience during the 1st quarter worth approximately $22,563,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Twist Bioscience in the 2nd quarter valued at approximately $19,722,000.

Insiders Place Their Bets

In other news, insider Dennis Cho sold 9,514 shares of the firm's stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the sale, the insider directly owned 63,789 shares of the company's stock, valued at $12,048,466.32. This trade represents a 12.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of Twist Bioscience stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,905,421.44. Following the completion of the sale, the senior vice president owned 106,632 shares in the company, valued at approximately $20,140,652.16. This trade represents a 8.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 495,279 shares of company stock worth $80,489,387. Company insiders own 3.08% of the company's stock.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST opened at $120.79 on Monday. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The company has a market cap of $7.57 billion, a P/E ratio of -54.41 and a beta of 2.25. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $219.71. The company has a 50-day moving average price of $151.35 and a 200 day moving average price of $91.08.

Key Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist launched MRD Express, potentially expanding its presence in minimal residual disease testing. Investors may look for further details on the product and business outlook around earnings. Article: Twist Bioscience stock enters earnings week after MRD Express launch
• Neutral Sentiment: CEO Emily Leproust and three other insiders sold a combined 6,677 shares at $135.40. The sales were disclosed as covering tax withholding on equity-award vesting, and each seller retained a substantial stake.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The provided article headline does not specify the report’s allegations, but its release appears to have hurt sentiment. Article: Twist Bioscience falls amid negative report

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on TWST shares. Guggenheim boosted their target price on Twist Bioscience from $107.00 to $212.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Canaccord Genuity Group upped their price target on Twist Bioscience from $120.00 to $205.00 and gave the stock a "buy" rating in a research note on Monday, October 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Twist Bioscience in a report on Monday, September 21st. Leerink Partners lifted their price objective on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an "outperform" rating in a research report on Tuesday, September 29th. Finally, Barclays lifted their price objective on shares of Twist Bioscience from $112.00 to $215.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Twist Bioscience has an average rating of "Hold" and a consensus target price of $153.00.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications.

The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.

Founded in 2013 and headquartered in South San Francisco, California, Twist serves customers in biotechnology, pharmaceutical, academic, agricultural and other industries around the world.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.